In May 2018, Auris inked an agreement with J&J’s division Ethicon’s NeuWave Medical subsidiary to develop systems for the robotically-assisted bronchoscopic ablation of lung lesions. J&J has been working with Alphabet‘s (NSDQ:GOOGL) Verily Life Sciences on Verb Surgical’s prototype robot-assisted surgery platform.
J&J wants to spend more for Auris than the smaller company’s $2 billion valuation from its latest funding round, the Bloomberg report said, citing anonymous sources. Redwood City, Calif.-based Auris closed on a $220 million equity financing round in November to help support its next-generation Monarch robotic interventional platform. The funding round brings the total raised for the Monarch platform up to $700 million, Auris Health said.
The Monarch platform has FDA clearance for diagnostic and therapeutic bronchoscopic procedures. The system features a controller interface for navigating the integrated flexible robotic endoscope into the periphery of the lung and combines traditional endoscopic views with computer-assisted navigation based on 3D patient models, the company said.
Auris’ system uses a game-like controller that allows for more direct control than existing one-handed interfaces to maneuver the endoscope.
Under the Auris-NeuWave agreement, both companies are helping to develop an integrated system for robotic control, navigation and application of bronchoscope-delivered microwave ablation. The bronchoscope in development will be equipped with a small camera and accessory channel to allow tools to enter the lungs through the mouth, Auris said in May.
Yesterday, J&J reported a return to black ink for the fourth quarter and set its financial forecast for the rest of the year. The New Brunswick, N.J.-based healthcare giant posted profits of $3.04 billion, or $1.12 per share, on sales of $20.39 billion for the quarter, for a 1.0% top-line gain over Q4 2017, when J&J posted losses of -$10.71 billion.
Auris declined to comment on the possible acquisition. J&J did not respond to a request for comment. J&J closed the $2.1 billion sale of its LifeScan blood glucose monitoring subsidiary to private equity player Platinum Equity in October 2018.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.